Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …

Targeted therapy with epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitors
(TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR …

Protein tyrosine kinases (PTKs) are a class of proteins with tyrosine kinase activity that
phosphorylate tyrosine residues of critical molecules in signaling pathways. Their basal …

The discovery that mutations in the EGFR gene are detected in up to 50% of lung
adenocarcinoma patients, along with the development of highly efficacious epidermal …

Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …

NSCLC is the leading cause of cancer mortality and represents a major challenge in cancer
therapy. Intrinsic and acquired anticancer drug resistance are promoted by hypoxia and HIF …

Epidermal growth factor receptor (EGFR) actively involves in modulation of various cancer
progression related mechanisms including angiogenesis, differentiation and migration …

Epidermal growth factor receptor (EGFR) is of great significance in mediating cell signaling
transduction and tumor behaviors. Currently, third-generation inhibitors of EGFR, especially …

According to global cancer data, lung cancer was the leading cause of cancer‑related death
in 2020. With the diversification of treatment strategies, the survival outcomes of patients with …

Simple Summary Osimertinib has revolutionized the treatment of EGFR-mutated tumors. Its
current applications include the first-line setting, second-line setting, as well as the adjuvant …